Tirzepatide vs Semaglutide

Tirzepatide and semaglutide are two of the most studied incretin-pathway peptides in modern metabolic research. They share a common GLP-1 receptor target, but their mechanisms diverge in ways that produce materially different signatures in published clinical and pre-clinical data.

Receptor mechanism

Semaglutide — single-agonist; activates only the GLP-1 receptor.
Tirzepatide — dual-agonist; activates GLP-1 and GIP receptors in one molecule.

The addition of GIP receptor activation gives tirzepatide a distinct downstream signaling profile, particularly around adipocyte biology and energy expenditure in pre-clinical models.

Clinical research at a glance

Semaglutide — the STEP and SUSTAIN trial programs reported ~15% mean body-weight reduction at the highest studied doses over 68 weeks.
Tirzepatide — the SURMOUNT trials reported ~20–22% mean body-weight reduction at the highest studied doses over 72 weeks.

Head-to-head trials (SURPASS-2) suggested superior glycemic and weight effects for tirzepatide vs semaglutide at the doses studied.

Half-life and dosing cadence

Semaglutide — half-life ~7 days; weekly dosing in research protocols.
Tirzepatide — half-life ~5 days; also typically weekly dosing in research protocols.

What about retatrutide?

Retatrutide takes the next step: GLP-1 + GIP + glucagon triple agonism. Phase 2 data reported even larger body-weight effects than either tirzepatide or semaglutide. Read the retatrutide page →

Buying for research

HerAmino stocks tirzepatide, semaglutide, and retatrutide for in-vitro laboratory research. Every batch is third-party tested for purity at ≥ 99% with a CoA included.

For in-vitro research use only. Not a drug, supplement, or treatment recommendation. Not evaluated by the FDA.